Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results
Posted innews OB/GYN & Women's Health Public Health

Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results

A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating centres, without increasing preterm rates.
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Posted innews Oncology

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and suggests clinical benefit — including signals versus historical second‑line FOLFOX — warranting randomized validation.
Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps
Posted inGastroenterology news

Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps

A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD were comparable, with a trend to higher complications in the colon.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Posted inGastroenterology news Oncology

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.
GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Posted inCardiology Diabetes & Endocrinology news

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults and those with ASCVD, HF, or kidney impairment.
Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort
Posted inCardiology Critical Care news

Baseline SGLT2 Inhibitor Use Associated with Lower Risk of Sepsis-Induced Cardiomyopathy and Improved Outcomes in Type 2 Diabetes: Insights from a Large Propensity-Matched Cohort

A large propensity-matched cohort study found that baseline SGLT2 inhibitor use versus DPP4 inhibitor therapy in adults with type 2 diabetes and infection was associated with lower 30-day sepsis-induced cardiomyopathy and improved 1-year mortality and cardiovascular outcomes; residual confounding and safety considerations warrant prospective trials.
Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results
Posted inGastroenterology Infectious Diseases news

Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results

In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained off‑therapy HBsAg loss endpoint at 24 weeks.
Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk
Posted inGastroenterology Infectious Diseases news

Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk

A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subgroups that may benefit from earlier antiviral therapy and intensified surveillance.